1 – 15 of 16
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Progressive improvement in wound healing with increased therapy in haemophilia B mice
(
- Contribution to journal › Article
- 2012
-
Mark
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
(
- Contribution to journal › Letter
-
Mark
Activated factor VII: my story.
(
- Contribution to journal › Article
- 2011
-
Mark
Joint protection in haemophilia
(
- Contribution to journal › Article
-
Mark
Monitoring rFVIIa 90 μg kg(-1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
(
- Contribution to journal › Article
-
Mark
First 20 years with recombinant FVIIa (NovoSeven).
(
- Contribution to journal › Article
-
Mark
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
(
- Contribution to journal › Article
- 2010
-
Mark
10th anniversary of the haemophilia/haemostasis Novo Nordisk symposium
(
- Chapter in Book/Report/Conference proceeding › Preface to conference proceeding
-
Mark
Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
(
- Contribution to journal › Article
- 2009
-
Mark
Bio-Distribution of Recombinant Factor VIIa: A Possible Explanation for the Hemostatic Effect of rFVIIa in Prophylaxis
(
- Contribution to journal › Published meeting abstract
-
Mark
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
(
- Contribution to journal › Article
- 2008
-
Mark
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article
- 2007
-
Mark
Recombinant factor VIIa: its background, development and clinical use.
(
- Contribution to journal › Article
- 2004
-
Mark
Recombinant FVIIa.
(
- Contribution to journal › Article
- 1996
-
Mark
Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
(
- Contribution to journal › Article